Ancor announces sale of Wellspring’s prescription business

Ancor Capital announced the sale of the Prescription Pharmaceutical Business of WellSpring Pharmaceutical Corporation.

“The sale of the business allows WellSpring to focus on its core competency of OTC products and contract manufacturing of pharmaceuticals” said Wendy Shusko, President of WellSpring Pharmaceutical. “Additionally, the strong capital base provided by this transaction and our investors will allow the company to aggressively pursue other OTC acquisitions” continued Ms. Shusko.

The latest news about Ancor Capital Partners and our portfolio companies.